You have attention deficit hyperactivity disorder (ADHD), but your doctor prescribed you stimulants. Sounds contradictory, but somehow it works. Ever wondered why?
The post Scientists think they’ve figured out how ADHD meds really work appeared first on Medical News Bulletin.
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast cancer in patients ineligible for PD-1/PD-L1 inhibitor therapy.
The agency granted priority review and approved datopotamab deruxtecan (Datroway; AstraZeneca, Daiichi Sankyo) based on results from the phase 3 TROPION-Breast02 trial, which were presented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology.
“Datopotamab deruxtecan is the first and only medicine to significantly
The currently available body of evidence is not strong enough to support vitamin supplementation as a treatment for dry eye disease, with particular gaps around vitamins C and B12, according to a review.
“Many patients [with dry eye disease] continue to experience persistent symptoms despite conventional therapies,” study author Hamidreza Heidari, MSc Optom, FBCLA, a PhD candidate at UNSW Sydney, told Healio. “There has been growing interest in the role of nutrition in addressing ocular surface diseases. ... However, the available evidence was scattered and inconsistent.”
Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved Hepcludex injection for the treatment of chronic hepatitis D infection in adults without cirrhosis or with compensated cirrhosis, according to a press release.
Hepcludex (bulevirtide-gmod, Gilead Sciences) is the first FDA-approved treatment for the condition.
“Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available,” Wendy Carter, DO, acting director of the Office of Infectious Diseases at FDA’s
WHO has raised its national risk assessment for the Ebola virus outbreak in the Democratic Republic of the Congo from “high” to “very high.”
WHO Director-General Tedros Adhanom Ghebreyesus, PhD, MSc, made the announcement Friday and said the outbreak being caused by a rare form of Ebola virus “is spreading rapidly.”
“We are now revising our risk assessment to ‘very high’ at the national level,” Tedros said, adding that the threat to the region remains “high” but the global risk is still “low.”
There are nearly
A rewritten charter for the CDC’s vaccine advisory committee that would have loosened the rules for membership to allow for less qualified members has been withdrawn.
A document published in the Federal Register on May 19 states that the renewal for the Advisory Committee on Immunization Practices charter was withdrawn due to “an administrative error in meeting the revised public notification timing requirements under the revised Federal Advisory Committee Act regulations, as amended in December 2025. As a result, the charter lapsed and the committee must be re-established.”
The previous
A 90-year-old white woman with a medical history of coronary artery disease, congestive heart failure and hypertension presented to her local eye doctor for a routine eye exam.
The patient also had a history of hyperlipidemia and multiple cutaneous squamous cell carcinoma lesions (status post Mohs excision).
Her chief concern was new drooping of her right upper eyelid. She said the drooping had been happening for about 6 months, with intermittent headaches and increased tearing from her right eye. Her headaches improved with Tylenol (acetaminophen, Kenvue). She denied any other visual or ocular
Cataract surgeons need to be aware of pseudoexfoliation syndrome, a systemic basement membrane disorder that compromises the structural integrity of the lens suspension system, pupil dilation and aqueous outflow pathways.
For the experienced surgeon, success is found in anticipating zonular failure before it becomes an intraoperative crisis. By focusing on a few critical pearls identified during the key stages of the procedure, a surgeon can navigate these high-risk cases with the same predictability as a routine operation.
Success in a pseudoexfoliation case begins at the slit lamp microscope
CHICAGO — The cognitive effects men with advanced prostate cancer experience during treatment may vary based on the therapy they receive, according to randomized phase 2 trial results presented at ASCO Annual Meeting.
An analysis of more than 100 men showed those randomly assigned to darolutamide (Nubeqa, Bayer) experienced significantly less cognitive decline over 24 weeks than those treated with enzalutamide (Xtandi; Astellas, Pfizer).
The findings provide valuable insights that can help guide treatment decision-making, lead author Alicia Morgans, MD, MPH, genitourinary medical oncologist and
In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab reduced risk for major adverse CV events compared with placebo, according to new data from the VESALIUS-CV trial.
As Healio previously reported, in the main results of VESALIUS-CV, the PCSK9 inhibitor evolocumab (Repatha, Amgen) lowered risk for major adverse CV events by 25% compared with placebo in patients with atherosclerosis or high-risk diabetes and LDL 90 mg/dL or more but no prior MI or stroke. At EuroPCR, Brian A. Bergmark, MD, interventional cardiologist at Brigham